Index

Entries for tables, figures, and boxes are noted in bold typeface.

2-component model for psychopathy, 324–327, 325
5-HT brain receptors and impulsive violence, 148–149
5-HT1A brain receptor and mood disorders, 118
5-HT1B brain receptor and impulsive violence, 118
and serotonin, 146
5-HT2A brain receptor and impulsive violence, 119
and serotonin, 146
5-HT3 brain receptor and dopamine levels, 119–120
acute hospital settings interventions, 42–44
risk assessment for violence, 42
addictions. See substance abuse
aggression
and amygdala size, 107–109
and dopamine levels in the brain, 81–82, 120–121
and psychopathy, 271–272
and serotonin, 114–120
Cal-VAT etiology guidelines, 156–157
definitions of, 53
intermittent explosive disorder, 105–106
typology of, 27, 27–28, 104–105
aggressive replacement therapy (ART), 286
agitation
and likelihood of future violence, 40, 41
Cal-Vat, 158–159, 160
medications, 43–44
psychopharmacological interventions, 213–216, 214
rating scales for, 212
alcohol
and 5-HT3 brain receptor, 119–120
and depression, 35
and violence risk, 36
altruistic filicide, 35
amisulpride, 202–209, 204–205
amygdala
and aggressive behaviors, 75, 77, 123
and prefrontal cortex, 110–113, 112
and psychopathy, 98
and schizophrenia, 139
structural and functional studies, 106–110, 107, 292
angry affect
and likelihood of future violence, 41, 41
and violence, 33
in emotional interventions, 284, 285
anterior cingulate cortex (ACC)
and aggression, 123–124
and amygdala responsivity, 110–113, 112
anti-impulsive aggressive agent (AIAA), 274–276
antipsychotic drugs. See also
medications
and deinstitutionalization of severely mentally ill, 1
and impulsive violence, 75, 78
and psychotic violence, 74, 78
for treatment-resistant schizophrenia, 225–226
high plasma, 234–240, 236
not responsive in predatory violence, 76
antisocial personality disorder (ASPD)
and criminalness, 292–293, 321–325
and psychopathy, 269, 273–274
clozapine to treat, 187–198, 189, 191–193
guidelines, 326
anxiety
and 5-HT1A brain receptor, 118
and likelihood of future violence, 41, 41, 58
and psychopathy, 98
AOT. See assisted outpatient treatment
arginine vasopressin (AVP) system, 121–122
aripiprazole
for agitation, 214, 215
for treatment-resistant schizophrenia, 227, 228–229, 235
asenapine
for agitation, 214, 216
for treatment-resistant schizophrenia, 227, 229, 235
ASPD. See antisocial personality disorder
assisted outpatient treatment (AOT), 7
attention deficit hyperactivity disorder (ADHD)
and dopamine levels in the brain, 86
and tryptophan, 115
Cal-VAT, 160
stimulants to treat, 81
auditory hallucinations. See
hallucinations and violence risk
Barratt Impulsiveness Scale (BIS), 136
Behavioral Activity Rating Scale (BARS), 212
behavioral management intervention
for forensic patients, 307–308
to prevent violence in hospitals, 42–43
binging, 91
bipolar disorder
and violence risk, 35, 56, 57–58
Cal-VAT, 160
numbers afflicted, 2
body-worn video, 318–319
Bolam test, 254
border personality disorder (BPD)
and psychosis, 272
clozapine to treat, 196–197
dopamine dysfunction and, 195
medications for, 187
brain. See also neurobiology
malfuction and violence, 73–78
prefrontal cortex and amygdala interactions, 110–113, 112
serotonin hypothesis, 145–151
striatum, 113–114
Brief Psychiatric Rating Scale (BPRS), 214
for psychopathy, 216
Broadmoor High Secure Hospital, 314, 318–320, 320
Brøset Violence Checklist (BVC)
aggressive behaviors, 28, 212
risk assessment, 42, 43
Buddi GPS tracker, 316–317
building security
in classification of inpatient violence, 12
in dimensional conceptualization of inpatient violence, 12
Bureau of Labor Statistics, 24
Buss-Perry Aggression Questionnaire (BPAQ), 105, 158

Cal-VAT. See California State Hospital Violence Assessment and Treatment Guidelines
California Department of State Hospitals (DSH)
ecological interventions, 263–267, 266–267
inpatient violence, 49–50
principles for treatment, 234–235
California State Hospital Violence Assessment and Treatment Guidelines (Cal-VAT)
assessment, 156–157
background, 155–156
case studies, 243–250
impulsive violence, 160–162
predatory violence, 162–164
psychopharmacological interventions, 158–159
psychosocial interventions, 164–167
psychotic violence, 159–160
setting and housing, 167–169
violence risk assessment, 157–158
callous-unemotional (CU) traits, 110
case studies
for treatment-resistant schizophrenia, 238–240
impulsive violence, 245–249
inpatient violence, 193, 193–195
predatory violence, 246–249
psychotic violence, 243–245, 249–250
schizophrenia, 203–206
to support Cal-VAT guidelines, 243–250
CATIE. See Clinical Antipsychotic Trials of Intervention Effectiveness
clozapine, 1
classification
of aggression, 27, 27–28
dementia and psychotic violence, 12, 12
Classification of Violence Risk (COVR), 12, 18, 21, 26, 158
Clearwater Sex Offender Programme, 326
Clinical Antipsychotic Trials of Intervention Effectiveness
(CATIE), 177–183, 180, 182
clinical assessment
and psychiatrist duty to protect, 65, 65–66
and TPR, 280–283
Cal-VAT, etiology guidelines, 156
importance of documentation in, 67–69
of psychiatric violence, 32–36, 40–41, 41
of psychopathy, 323–324
serotonin and impulsive aggression, 147, 150–151
Clinical Global Impression (CGI) scale and clozapine, 188–190
for combination clozapine and amisulpride, 203
closed circuit television (CCTV), 317–319, 318
clozapine
for ASPD, 187–198
for psychopathy, 216–217
for psychotic violence, 244–245, 248–249
for schizophrenia, 202–209, 204
for treatment-resistant schizophrenia, 226–227, 227, 235–236, 249–250
cognitive behavioral therapy and impulsive violence, 93
in TPR, 283, 284
cognitive impairment
Cal-VAT psychosocial intervention, 167
self-empowerment of, 283–284
Cohen–Mansfield Agitation Inventory (CMAI), 158
command hallucinations, 33–34
community hospital. See mental hospitals
community treatment disorders. See assisted outpatient treatment computed tomography (CT), 82–83, 83
conditional release for mental illness, 7–8
correctional setting. See also mental hospitals
and treatment of mentally ill, 10–11
and violence risk assessment, 20–21
violent inpatient treatment, 12–14
cortisol, 122–124
court order
and committing forensic patients to a state hospital, 49–50, 52
and inpatient aggression, 56, 60
and treatment of mentally ill, 7–8, 252–255, 253
for psychiatrists to protect, 64–71
interventions, 305–306
criminalness. See also forensic patients, recidivism
and impulsive violence, 90–91, 325, 327
and mental health courts, 8
and psychopathy, 270–271
and schizophrenia, 203–206, 327–328
Cal-VAT, 165
clozapine to treat, 187–198, 189, 191, 193
housing, 293–296, 294
relationship with mental illness, 291–293, 291, 303–304
sequential intercept mapping workshops for, 304, 305
treatment, 296–298
Crisis Intervention Team (CIT), 304–305
Critical Time Intervention, 306
CT. See computed tomography
culture of care, 281–283
culture of incarceration, 309
data practices with inpatient violence, 12, 12, 19–20, 21, 67–69
dehospitalization of severely mentally ill, 2–7
delusions
and schizophrenia, 140
and violence risk, 32–33, 32–33
demographics
and inpatient aggression, 52, 54–56, 55, 60
of forensic patients by legal class, 52
Department of Justice National Crime Victimization Survey for 1993 through 1999, 24
depression
and violence risk, 34–35, 56, 57–58
Cal-VAT, 160
technology to monitor, 314
Diagnostic and Statistical Manual of Mental Disorders (DSM), 51, 73, 151, 188, 269
dialectical behavioral therapy (DBT)
and psychotic and impulsive violence, 78
for impulsive violence, 93, 247–248, 307
documentation. See data practices with inpatient violence
dopamine overactivity
and 5-HT3 brain receptor, 119–120
and aggression, 81–82, 120–121, 195
and psychotic violence, 74
and striatum, 113
psychopharmacological interventions, 221–222, 223
role of in violence, 76–77, 92
with TBI, 81–87
Index

drug abuse
and insensitivity–compulsivity
behavior, 90
as confounding factor for treatment,
76
drug court, 305
duty to protect, 64–71
Dynamic Appraisal of Situational
Aggression (DASA)
and risk assessment, 28, 42, 43
Cal-VAT guidelines, 158
ecological systems theory, 263
electronic monitoring of patients,
315–317
emotional interventions, 284–285,
285
and likelihood of future violence,
41–42
Cal-VAT etiology guidelines,
156–157
ecological systems theory, 263–267,
266–267
environmental interventions, 44
Epidemiological Catchment Area
Survey (ECA) surveys, 3–4, 33
ethnicity and aggression,
51–52, 54–55, 55, 60
European First-Episode Schizophrenia
Trial (EUFEST), 177, 181–183
factors behind deinstitutionalization
of mentally ill, 2–7
factors for criminal behavior, 292–293
factors for description for psychopathy,
96, 100
factors for likelihood of inpatient
violence, 40–42, 69–70
factors for schizophrenia, 136
families of mentally ill, 4
fear in interventions, 285, 285
filicide, 34
fluoro-deoxyglucose positron emission
tomography (FDG-PET), 109
fluphenazine, 235–236, 236, 238–239
focal brain lesions
and dopamine levels in the brain,
81–82, 84–87
CT scans for focal brain lesions,
82–83, 83
Forensic Assertive Community
Treatment, 306
forensic patients. See also criminalness
ecological interventions, 263–267,
266–267
in mental hospitals, 10–14
intervention guidelines, 252–255,
253, 258–261, 259
legal classes of, 52
Gage, Phineas, 96, 97
gender and aggression, 52, 54, 54–55,
59
genetic analysis
and dopamine levels in the brain,
120–121
and psychopathy, 98
for aggression, 83
MAOA, 117–118
of serotonin, 116
of vasopressin, 121–122
global positioning systems (GPS),
315–317, 316–317
guidelines
ASPD, 326
Cal-VAT, 155–169
for forensic patient interventions,
252–255, 253, 258–261, 260
for treatment-resistant
schizophrenia, 223–225
habit
as stimulus–response learning
system, 90–92
treatment for impulsive violence as,
92–94
hallucinations and violence risk, 33–34
haloperidol
for agitation, 214
for treatment-resistant
schizophrenia, 235–236, 236, 239
Hare Psychopathy Checklist (PCL-R),
12, 24–27, 26, 158, 188, 192, 195,
269, 271–272, 323–324
high plasma level antipsychotics,
234–240, 236
Historical, Clinical, Risk Management-
20 (HCR-20)
and community, 25–27, 26
and risk assessment, 12, 18, 21, 42
Cal-VAT, 158
homicides
and psychopathy, 96
and schizophrenia, 4
and severe mental illness, 6, 6–7
hospital staff. See also mental health
professionals
and likelihood of future violence, 41
Cal-VAT etiology guidelines, 157
psychiatrists duty to protect, 64–71
reporting violent situations, 39–40,
40, 50
hostility
CATIE definition, 177–178, 183
scales for, 212
housing. See mental hospitals
Iloperidone, 227, 229
imminent aggression, 27
impulsive violence
and 5-HT1B brain receptor, 118
and 5-HT2A brain receptor, 119
and compulsive behaviors, 90
and psychopathy, 271–272, 274–276
and serotonin, 145–151, 146
and striatum, 113–114
areas of the brain affected, 74–75,
74–75, 77
as syndrome of violence, 73–74, 74,
216
as the inability to resist urges, 90–91
Cal-VAT guidelines, 156, 160–162,
166–167
case studies, 245–249
interventions, 78, 92–94, 221–229
maladaptations in brain circuitry,
91–92, 92
prefrontal cortex rewards for, 92–93
schizophrenic, 136–141
incompetence to stand trial, 260
independent forensic evaluation
and forensic interventions, 252–255,
253
in dimensional conceptualization
of inpatient violence, 10, 12, 12
inpatient violence
and impulsivity, 136
case studies, 192, 193–195
definitions of aggression, 53
in community hospitals, 39–45
motivators of, 11, 11
psychopharmacological interventions
for, 212–218
risk assessment, 24–29
treatment, 12–14
institutional aggression, 25–28
instrumental aggression, 145, 216
intermittent explosive disorder
and aggression, 105–106
and psychopathy, 273–274
being common, 145
Cal-VAT, 160
interventions. See also treatment
community re-entry, 306
ecological, 263–267, 266–267
for forensic inpatients, 252–255,
258–261, 259
for psychopathy, 269–276, 323–328
in dimensional conceptualization
of inpatient violence, 29
police-based, 304–305
psychosocial, 279–287
technology to monitor, 314–320
to prevent violence in hospitals, 39,
42–44
involuntary treatment option for
mental illness
AOT, 7
conditional release, 7–8
court-ordered, 305–306
mental health courts, 8

Kendra’s Law, 7
Laura’s Law, 7
legal classes
and inpatient aggression, 60
of forensic patients, 52
legal commitment. See court order
legal context
and deinstitutionalization of severely mentally ill, 1
violence risk assessment, 17
legal error, 69
length of stay and patient aggression, 59
lithium, 248–249
lorazepam, 214
loxapine, 214, 215
lurasidone, 227, 229, 235

MacArthur Study of Mental Disorder and Violence, 33
MacArthur Violence Risk Assessment Study, 35
MacArthur–Maudsley Delusions Assessment Schedule, 33
magnetic resonance imaging (MRI) and amygdala responsivity, 109–110, 292, 299
and serotonin, 113–114
of schizophrenia, 139–140
mania. See bipolar disorder
MAOA. See monoamine oxidase A
mass killings. See homicides
McNiel–Binder Violence Screening Checklist (VSC), 28, 42, 43
medications. See also antipsychotic drugs, psychopharmacological interventions
and violence, 4, 7
Cal-VAT etiology guidelines, 156
failure of, 222–223, 224
to treat aggression, 81–82
Medium Secure Service, 316–317,
316–317. See also mental hospitals
Mendota Juvenile Treatment Center (MJTC), 285
mental health professionals. See also hospital staff
and risk for violence, 24, 264
TPR training, 281–282
mental hospitals. See also Medium Secure Service, correctional setting and forensic interventions,
252–255, 258–261, 283, 293–296, 294
and inpatient aggression, 11–13, 39–45, 49–62
as factor in deinstitutionalization, 1
Cal-VAT guidelines, 157, 167–169
conditional release, 7–8
incarceration and lack of violence, 1, 5
length of stay and aggression, 59
predatory violence exceeding security, 246–247
violence increase in, 10–14
mental illness
and criminality, 291–293, 291,
303–304
and homicides, 6, 6–7
involuntary treatment option, 7–8
recidivism, 303–304
mirtazapine, 247–248
MISSION-Criminal Justice, 308–309
monoamine oxidase A (MAOA), 117–118
mood disorders. See also psychosis and 5-HT1A brain receptor, 118
and violence risk, 34–35
Cal-VAT guidelines, 161
technology to monitor, 314
Moral Reconciliation Therapy, 308
motion detector technology, 319–320, 320
murder. See homicides
narcissism, 99, 100
National Alliance for the Mentally Ill (NAMI), 4
National Institute of Mental Health (NIMH), 2
neurobiology. See also brain after penetrating brain injury, 81–87
and dopamine levels in the brain, 120–121
and impulsive violence addiction, 90–94
and medication failure, 222–223, 224
and serotonin, 114–120
of psychopathy, 96–101, 272–273
of schizophrenic impulsive violence, 136–141, 139, 234
of violence, 104–114, 291–292
Neuropsychiatric Inventory (NPI-a), 82
neurotransmitters (brain)
and schizophrenia, 136–141
and serotonin, 147
and violence, 76–77, 114–125
New Hampshire State Hospital, 7
New York Times (newspaper), 4–5
Occupational Safety and Health Administration (OSHA), 24
olanzapine
CATIE study, 183
for agitation, 213, 214
for psychopathy, 217
for psychotic violence, 243–244
for treatment-resistant schizophrenia, 227, 228, 235, 236, 236, 239–240
orbitofrontal cortex (OFC)
and aggression, 123–124
and amygdala responsivity, 110–113, 112
response to negative pictures, 137
Overt Aggression Scale (OAS), 212
paliperidone, 227, 235
patient–patient factors to violence, 40–41, 41
peer support and recovery, 310
persecutory delusions. See delusions persistent aggressive behavior. See psychopathy
pharmacology. See psychopharmacological interventions
Point Subtraction Aggression Paradigm (PSAP), 109, 137, 141
police-based interventions, 304–305
Positive and Negative Syndrome Scale (PANSS), 177–179, 181–183, 212
positron emission tomography (PET) and 5-HT2A brain receptor, 119
and brain receptors, 125
and dopamine levels in the brain, 120–121
and schizophrenia, 138
post-traumatic stress disorder and TPR, 309
Cal-VAT guidelines, 160
preyatory violence
and hypactive amygdala, 75
areas of the brain affected, 75
as syndrome of violence, 73–74, 74
Cal-VAT guidelines, 156, 162–164, 165, 166–167
case studies, 246–249
prefrontal cortex
and amygdala interactions, 110–113, 112
and focal brain lesions, 81–82
and impulsive–compulsive behavior, 92–93
and psychopathy, 98–99, 99–100
and stratum, 113–114
proactive aggression
and amygdala responsivity, 110
components of, 105
psychiatric setting. See mental hospitals

335
Index

Psychopathic Personality Inventory, 120
psychopathy
and areas of the brain, 96–101, 97, 99–100
and childhood adversity, 97
clozapine to treat, 197
genetic analysis for, 98
interventions for, 269–276, 323–328
medications for, 100
psychopharmalogical interventions, 216–218
Psychopathy Checklist. See Hare
Psychopathy Checklist
psychopharmalogical interventions. See also medications
and serotonin, 114–120
clozapine, 187–198
for psychopathy, 100, 273–276
for schizophrenia, 177–183, 180–181
for treatment-resistant schizophrenia, 202–209, 204, 221–229, 234–240
reducing impulse violence, 73
to prevent violence in hospitals, 43–44, 212–218
to support Cal-VAT guidelines, 158–164, 160–162, 243–250
psychosis, 32–33, 32–34, 56, 57, 327.
See also mood disorders
psychosocial interventions
Cal-VAT guidelines, 163, 164–167, 165
contextually anchored, 279–287
psychotic violence
areas of the brain affected, 74, 75
as syndrome of violence, 73–74, 74
Cal-VAT guidelines, 156, 159–160, 159–160, 161, 165, 166
case studies, 243–245, 249–250
interventions, 78, 221–222, 222
PubMed database, 39
quetiapine, 227, 228, 235
RAGE-Control intervention, 286
reactive violence. See impulsive violence
reason for rise in violence
and forensic mental health systems, 10–14
deinstitutionalization of severely mentally ill, 7–8
recidivism. See also criminalness
2-component model for psychopathy, 325–327
and mental illness, 303–304
and violence risk reduction, 307–309
peer support to prevent, 310
Recovery Inspired Skills Enhancement (RISE), 167
Research Domain Criteria (RDoC)
and schizophrenia, 137
in psychopathology, 73–74, 74, 77
responsivity principle, 165
risk assessment. See also violence risk assessment
for inpatient violence, 42, 43
importance of documentation in, 67–69
of psychiatrists duty to protect, 69–71
of psychosis and mood disorders, 35–36, 36
of violence with clozapine, 192–193
Risk-Need-Responsivity Model
Cal-VAT, 164
risperidone, 227, 228, 235–236, 236
safety
and behavioral interventions, 42–43
and collaborative forensic treatment, 306
and treatment of mentally ill, 10–11
and violent inpatient treatment, 12–14
246–247
psychiatrists duty to protect, 64–71
schizoaffective disorder, 56, 57–58
schizophrenia
and homicides in 1980s, 3
and homicides, 4
and impulsive violence, 136–141, 139
and substance abuse, 6, 76
and TCO, 33
and violence, 4, 34, 36, 57–58, 327–328
Cal-VAT guidelines, 159
numbers afflicted, 2
secure continuous remote alcohol monitoring (SCRAM), 315
selective serotonin reuptake inhibitor (SSRI)
and cortisol levels, 122
and psychopathy, 273
and serotonin, 115, 149–150, 150
Sensitizing Providers to the Effects of Correctional Incarceration on Treatment and Risk Management (SPECTRIM), 309
sequential intercept mapping model, 304, 305
serotonin
and aggression, 114–120, 124, 145–151, 146, 196
and amygdala responsiveness, 113
and psychopathy, 273
and striatum, 113–114
imbalances of, 76–77
serotonin transporter genes, 116–117
severe mental illness
and homicides, 2–3, 6–7, 6
and violent behavior, 4–7, 5
rate of, 2
treatment percentages, 2
Sex Offender Risk Appraisal Guide (SORAG), 42
shame in interventions, 285
Short Term Assessment of Risk and Treatability (START), 12, 158
single nucleotide polymorphism, in dopamine system (SNP)
and dopamine levels in the brain, 84–87
and tryptophan hydroxylase-2, 116 with TBI, 81–82, 84
Social Security Disability Insurance (SSDI), 1
SSRI. See selective serotonin reuptake inhibitor
staff. See mental health professionals
Staff Observation Aggression Scale (SOAS), 158
steroid hormones, 122–124
striatum
and aggression, 124
and schizophrenia, 139
structural professional judgment of violence risk assessment, 18, 25, 28
structured clinical instruments, 42
substance abuse
and mental illness, 303
and psychopathy, 274
and schizophrenia, 6
in dimensional conceptualization of inpatient violence, 12, 12, 308–309
peer support, 310
psychopharmalogical interventions, 213
Substance Abuse and Mental Health Services Administration (SAMHSA), 309–310
suicide
and homicides, 34–35, 36
and serotonin, 145–147
technology to prevent, 314
Supplemental Security Income (SSI), 1
Tarasoff (legal decision), 64–65
Taylor Aggression Paradigm (TAP), 137, 141
TBI. See traumatic brain injury
TCO. See threat control-override symptoms
technology in interventions, 314–320
testosterone, 122–124
The International Handbook of
Psychopathic Disorders and the
Law, 272
threat in Tarasoff situations, 66–67, 67
perception in impulsive and
psychotic violence, 74–75, 77
threat control-override symptoms
(TCO), 32–33, 36
TPR. See trauma-informed recovery
transcranial magnetic stimulation
(TMS), 140–141
trauma-informed recovery (TPR).
See also traumatic brain injury
and violence risk, 283–286, 284–285
clinical assessment, 280–283
mission of, 279–280, 280, 309–310
perspective, 279–280
traumatic brain injury (TBI). See also
trauma-informed recovery
and dopamine levels in the brain, 81–82
Cal-VAT guidelines, 160
CT scans for focal brain lesions, 82–83
treatment. See also interventions
and safety, 10–11

and violent behavior among
mentally ill, 7–8
for criminalness, 296–298
in dimensional conceptualization of
inpatient violence, 12–13, 12–13
of schizophrenia, 139–140
serotonin and impulsive aggression,
149–150, 150
trifluoperazine, 238
tryptophan
and aggression, 114–115
and serotonin, 146
tryptophan hydroxylase-2, 116
typology. See classification
untreated mental illness, 3–5, 5
valproate, 235
vasopressin, 121–122
violence
as a medical syndrome, 10, 73–78, 90
as process in TPR, 280
prevalence in mental hospital setting,
40, 40, 49–62
psychopharmalogical interventions
for, 212–218
reduction in forensic institutions,
263–267, 266–267
violence increase
and untreated mental illness, 3–5
in mental hospitals, 10–14
to families of mentally ill, 4
Violence Prediction Scheme (VPS), 42
violence prevention
community programs, 306–310
TPR, 285–286
Violence Reduction Program, 326
Violence Risk Appraisal Guide
(VRAG), 18, 21, 25–27, 26, 42, 158
violence risk assessment. See also risk
assessment
2-component model for
psychopathy, 325, 325–327
and recidivism, 307–309
Cal-VAT guidelines, 157–158
development of, 24–27, 26
evolution of, 17–22, 18
for forensic patient interventions,
258–259, 259
in dimensional conceptualization of
inpatient violence, 12–14, 12–13
of aggression, 24–29
TPR, 283–285, 284–285
Violence Risk Scale (VRS), 158,
325–327, 325
Violence Risk Screening-10 (V-RISK-10),
12, 158
ziprasidone
for agitation, 213, 214
for treatment-resistant
schizophrenia, 227, 228, 235